Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
T. Rowe Price Investment Management, Inc. amended its Schedule 13G/A to report beneficial ownership of 4,028,202 shares of Black Diamond Therapeutics I common stock, representing 7.0% of the class as of 06/30/2026. The filing lists 3,992,774 shares as sole voting power and 4,028,202 as sole dispositive power. The filing also includes a statement that the filer "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
Black Diamond Therapeutics director Ali Behbahani received a grant of stock options covering 40,000 shares of common stock at an exercise price of $1.71 per share. The options expire on June 25, 2036 and were granted as a compensation award, not an open-market purchase.
According to the terms, all 40,000 options will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Behbahani continues to serve as a director through that date. After this grant, his directly held option position reported in this filing totals 40,000 options.
Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock. These options have an exercise price of $1.71 per share and are held directly in his name.
The options vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve through that vesting date. After this grant, he holds options to acquire 40,000 shares, and there are no open-market purchases or sales reported in this filing.
Black Diamond Therapeutics director Garry E. Menzel received a stock option award for 40,000 shares of common stock. The option has an exercise price of $1.71 per share and expires on June 25, 2036. It was granted as a compensation award rather than a market purchase or sale.
The option will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to his continued service through that date. Following this grant, he holds 40,000 option-based rights directly.
Black Diamond Therapeutics director Raman Prakash received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. Following this grant, Prakash holds options for 40,000 underlying shares.
According to the vesting terms, the options will become fully exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve the company through that vesting date.
Black Diamond Therapeutics director Kapil Dhingra received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. All 40,000 options are reported as held directly following this award.
According to the grant terms, the options will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Dhingra continues to serve through the vesting date. This is a compensation-related award, not an open-market purchase.
Black Diamond Therapeutics director Shannon Campbell received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036.
According to the terms, the entire option grant will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Campbell continues to serve through that date. Following this grant, Campbell holds options for 40,000 underlying shares directly.
Black Diamond Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Of 57,301,774 common shares entitled to vote as of April 28, 2026, 44,690,495 were represented, establishing a quorum. Stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors for three-year terms. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on a non-binding basis, the compensation of the named executive officers and indicated a preference to hold this advisory vote every year. The company will conduct future say-on-pay votes annually until the next required vote on frequency.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 8,961 shares of common stock at $1.66 per share. These shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in which he elected stock instead of cash for annual board service.
After this award, Behbahani directly holds 102,529 shares of common stock. Separately, 4,448,757 shares are reported as indirectly held by New Enterprise Associates 16, L.P., where he is affiliated through general partner entities. He disclaims beneficial ownership of portions of those indirect holdings in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 7,907 shares of common stock as equity compensation. The shares were granted in lieu of cash fees under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy at a reference price of $1.66 per share, based on the June 18, 2026 closing price. Following this award, Prakash directly holds 45,039 shares.